Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2019167 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| SCHEMBL31709974 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| SCHEMBL21551907 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| SCHEMBL30069234 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| SCHEMBL2019171 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| SCHEMBL30746800 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| SCHEMBL539630 | 1.00 | GLP1R (1.00) | GLP1RAMY1A | |
| Hydrochloric Acid SCHEMBL21552133 | 0.99 | GLP1R (1.00) | GLP1RAMY1A | |
| Hydrochloric Acid SCHEMBL21552139 | 0.99 | GLP1R (1.00) | GLP1RAMY1A | |
| Hydrochloric Acid SCHEMBL21552137 | 0.99 | GLP1R (1.00) | GLP1RAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790549-A1 | THERAPEUTIC USES OF GLP1R AGONISTS | vTv Therapeutics LLC (US) | 2021-03-17 | — | — | EP | claimed |
| US-20210023072-A1 | THERAPEUTIC USES OF GLP1R AGONISTS | VTV THERAPEUTICS LLC | 2021-01-28 | — | — | US | claimed |
| WO-2019217165-A1 | THERAPEUTIC USES OF GLP1R AGONISTS | VTV THERAPEUTICS LLC (US) | 2019-11-14 | — | — | WO | claimed |
| EP-2945618-B1 | COMBINATIONS OF A GLP1R AGONIST AND METFORMIN AND USE THEREOF FOR THE TREATMENT OF TYPE 2 DIABETES AND OTHER DISORDERS | VTV THERAPEUTICS LLC (US) | 2018-06-13 | — | — | EP | claimed |
| EP-2413693-B1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2015-09-09 | — | — | EP | claimed |
| US-8987295-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-03-24 | — | — | US | claimed |
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-18 | — | — | US | claimed |
| US-8383644-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-02-26 | — | — | US | claimed |
| US-20250325536-A1 | THERAPEUTIC USES OF GLP1R AGONISTS | VTV THERAPEUTICS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-3790549-A1 | THERAPEUTIC USES OF GLP1R AGONISTS | vTv Therapeutics LLC (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20210023072-A1 | THERAPEUTIC USES OF GLP1R AGONISTS | VTV THERAPEUTICS LLC | 2021-01-28 | — | — | US | disclosed |
| WO-2019217165-A1 | THERAPEUTIC USES OF GLP1R AGONISTS | VTV THERAPEUTICS LLC (US) | 2019-11-14 | — | — | WO | disclosed |
| EP-2945618-B1 | COMBINATIONS OF A GLP1R AGONIST AND METFORMIN AND USE THEREOF FOR THE TREATMENT OF TYPE 2 DIABETES AND OTHER DISORDERS | VTV THERAPEUTICS LLC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20150313908-A1 | Combinations of a GLP1R Agonist and Metformin and Use Thereof for the Treatment of Type 2 Diabetes and Other Disorders | VTV THERAPEUTICS LLC | 2015-11-05 | — | — | US | disclosed |
| US-8987295-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8383644-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2413693-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TransTech Pharma, Inc (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110160198-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2010114824-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TRANSTECH PHARMA INC (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885AMY1A 296/4885 |
| US-20110160198-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLP1R, GIPR, GPR119 | GLP1R 1/4885AMY1A 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.